European Oncology Biosimilars Set to Generate €2 Billion in Healthcare Savings by 2021
Key Insights
IQVIA forecasts potential savings of €2 billion across European markets by 2021 through biosimilar versions of key oncology drugs including rituximab, trastuzumab, and bevacizumab.
Healthcare systems must focus on three critical factors for successful biosimilar adoption: evidence generation through real-world data, comprehensive stakeholder education, and aligned financial incentives.
While biosimilar savings represent 20% of biologics expenditure, strategic planning is needed to effectively allocate these funds for healthcare system sustainability.
The European healthcare landscape is poised for significant cost savings as biosimilar versions of major oncology drugs enter the market, offering a crucial opportunity to manage escalating healthcare expenses. According to a new IQVIA Institute for Human Data Science study, biosimilars could generate savings of nearly €2 billion across European markets by 2021.
Key Oncology Biosimilars Driving Savings
The projected savings will primarily come from biosimilar versions of three blockbuster medications: MabThera/Rituxan (rituximab), Herceptin (trastuzumab), and Avastin (bevacizumab). These drugs currently represent a substantial portion of European oncology spending, which reached €24.2 billion in 2016, marking a €2.9 billion increase from the previous year.
While the anticipated €2 billion in savings represents less than 10% of total oncology drug expenditure, it accounts for 20% of biologics spending and approximately two-thirds of the year-over-year increase in oncology costs.
Market Dynamics and Industry Response
Original drug manufacturers are adapting their strategies to maintain market position. Roche, for instance, has successfully retained market share by introducing an improved subcutaneous formulation of trastuzumab, which now accounts for roughly 20% of trastuzumab volume across Europe.
New entrants like Celltrion and Samsung (search) have already made significant impacts in European markets, particularly in Scandinavian countries where some originator products have experienced nearly complete market share loss due to competitive pricing.
Critical Success Factors for Biosimilar Adoption
Evidence Generation
Despite stringent regulatory requirements, many oncologists remain cautious about biosimilar adoption. Real-world evidence (RWE) and comprehensive databases will be crucial for building confidence among healthcare providers. Manufacturers and payers must invest in these resources to address safety and quality concerns effectively.
Stakeholder Education
Professional organizations like ESMO (search) are actively working to educate healthcare professionals about biosimilars. This educational initiative must extend beyond oncologists to include nurses, pharmacists, and patients to ensure widespread acceptance and appropriate use.
Financial Incentives
Healthcare systems must establish clear frameworks for allocating biosimilar-generated savings. Key questions remain about whether these funds should support increased patient access, fund innovation, or contribute to general healthcare budgets.
Future Implications
While biosimilars present a significant opportunity for cost management, they alone cannot solve healthcare sustainability challenges. Success will require coordinated efforts among stakeholders to maximize uptake and ensure appropriate allocation of savings.
The market is likely to consolidate over time, with only the most successful biosimilar manufacturers maintaining their presence. This evolution will shape the competitive landscape and influence future pricing dynamics in the oncology sector.